Access to cancer genetic testing unequal worldwide: New Lancet Commission
The team estimated that seven to eight million (70-80 lakh) people with cancer worldwide need standard-of-care molecular testing every year
A new Lancet Oncology commission reveals significant disparities in access to cancer genetic testing and targeted treatments worldwide. Only 2% of biomarker-based cancer trials involve low- and middle-income countries (LMICs), while almost 81% take place in high-income nations. The rapid growth of precision oncology has led to escalating costs and complexity outpacing the health benefits, with global cancer drug spending increasing by 75% over five years, reaching $252 billion in 2024 and projected to reach $441 billion by 2029.
The researchers evaluated global clinical trial and genomic data, as well as national cancer programs. They estimated that seven to eight million people with cancer annually require standard-of-care molecular testing, but coverage remains inadequate, especially in LMICs. For instance, about half of the 3.14 lakh women with ovarian cancer eligible for BRCA testing each year do not receive it, primarily due to low testing rates in LMICs.
To assist health systems, the commission proposes a framework for prioritizing molecular tests and matched therapies, along with a system-readiness assessment tool. They have also developed a workforce-competency framework and principles for responsible data-sharing. The commission outlines 10 core recommendations for integrating precision oncology equitably into cancer control and universal health coverage, along with a phased implementation roadmap.
Written by urgent.news from The Hindu Health's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
